Evidence map›Paper›PMID 40495520›Full record

ArticleEuropean psychiatry : the journal of the Association of European Psychiatrists2025

Pharmacological treatment and psychiatric polypharmacy in forensic psychiatric care in Sweden.

Taalke Maria Sitter, Suvi Virtanen, Hanna Edberg, Peter Andiné, Anja Fernqvist, Ebba Noland, Tatja Hirvikoski, Thomas Nilsson, Zheng Chang

Abstract read
In one paragraph

Article in European psychiatry : the journal of the Association of European Psychiatrists, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Taalke Maria SitterDepartment of Medical Epidemiology and Biostatistics, https://ror.org/056d84691Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0007-3543-131X
Suvi VirtanenDepartment of Medical Epidemiology and Biostatistics, https://ror.org/056d84691Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-2779-3384
Hanna EdbergDepartment of Medical Epidemiology and Biostatistics, https://ror.org/056d84691Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-7320-6091
Peter AndinéDepartment of Psychiatry and Neurochemistry, Centre for Ethics, Law and Mental Health (CELAM), Institute of Neuroscience and Physiology, Sahlgrenska Academy, https://ror.org/01tm6cn81University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-6748-9619
Anja FernqvistDepartment of Psychiatry and Neurochemistry, Centre for Ethics, Law and Mental Health (CELAM), Institute of Neuroscience and Physiology, Sahlgrenska Academy, https://ror.org/01tm6cn81University of Gothenburg, Gothenburg, Sweden.ORCID 0009-0006-2962-3430
Ebba NolandDepartment of Social Work, https://ror.org/05kb8h459Umeå University, Umeå, Sweden.ORCID 0000-0002-0171-5185
Tatja HirvikoskiCentre for Psychiatry Research, Region Stockholm, Stockholm, Sweden.
Thomas NilssonForensic Psychiatry, https://ror.org/04vgqjj36Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0002-7771-3696
Zheng ChangDepartment of Medical Epidemiology and Biostatistics, https://ror.org/056d84691Karolinska Institutet, Stockholm, Sweden.

Funding

Forskningsrådet om Hälsa, Arbetsliv och Välfärd F-112648Vetenskapsrådet F-112647
6 · The paper itself

Abstract

backgroundPatients in forensic psychiatric care (FPC) are commonly treated with a wide range of psychotropic medications. There is, however, a lack of understanding regarding how pharmacological treatment and psychotropic polypharmacy are used throughout care.

methodThis register-based cohort study included patients admitted to FPC in Sweden between 2009 and 2020. We estimated the prevalence of the use of major psychotropic medication, as well as psychotropic polypharmacy, at admission and discharge. We also examined the change in antipsychotic use after admission.

resultsIn total, 1962 patients were included. Antipsychotics were the most used psychotropic medication class, with 86.2% (95%CI: 84.5-87.8) of patients receiving at least one typical or atypical antipsychotic at admission. Changes in the antipsychotic regime were more common at the beginning of FPC, compared to later time points. Within the subgroup of patients discharged during the study period (n = 561), there was a reduction in the use of typical antipsychotics (admission: 34.9%; discharge: 26.6%) and hypnotics and sedatives (admission: 37.4%; discharge: 28.1%). Other major medication classes remained relatively stable. The prevalence of psychiatric polypharmacy at admission was 70.6% (95%CI: 68.5-72.7) and remained similar during care.

conclusionsOur study documented a high prevalence of antipsychotic use and psychotropic polypharmacy through FPC. Further, a high level of off-label antipsychotic use and antipsychotic polypharmacy was observed. Stronger evidence regarding the effectiveness and safety of these treatment strategies is needed.

Indexed as

Antipsychotic AgentsForensic PsychiatryMental DisordersPolypharmacyPsychotropic DrugsRegistriesAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedSwedenYoung AdultAntipsychotic AgentsPsychotropic Drugsantipsychoticscoercive measuresforensic psychiatric carepharmacological treatmentrecidivism

Identifiers

PMID40495520
PMCPMC12188328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.